buy

SELLAS Life Sciences Group Inc buy melinda

SELLAS Life Sciences Group Inc

Start price

€62.24

/ 50%

Target price

07.11.18

Performance (%)

End price

€76.40

Summary

This prediction ended on with a price of €76.40. The prediction had a final performance of . melinda has 50% into this prediction

SELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.

Feedback

Performance without dividends (%)

Name	1w	1m	1y	3y
SELLAS Life Sciences Group Inc
iShares Core DAX®
iShares Nasdaq 100
iShares Nikkei 225®
iShares S&P 500

Comments by melinda for this prediction

In the thread SELLAS Life Sciences Group Inc diskutieren

Prediction Buy

Perf. (%)

Target price 2.706

Change

Ends at

SecteurProduits pharmaceutiques Agenda 19/10 Présentation

Métier

Develop biopharmaceuticals

SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutic for a broad range of indications.

Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein.

The company was founded on April 3, 2006 and is headquartered in New York, NY.

Nombre d'employés : 11 personnes.

melinda